Efmoroctocog alfa
Identification
- Name
- Efmoroctocog alfa
- Accession Number
- DB11607
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Blood factors / Fusion proteins / Peptides - Description
Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as Moroctocog alfa1. It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII. Patients with this disorder are more susceptible to recurrent bleeding episodes and excessive bleeding following minor traumatic injuries or surgical procedures 1. Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients 1,2. Prophylaxis has also shown to reduce the formation of neutralizing anti-FVIII antibodies, or inhibitors 2.
Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. Efmoroctocog alfa is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein Label. The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products 1.
Other drug products with similar structure and function to Efmoroctocog alfa include Moroctocog alfa, which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function, and Antihemophilic factor human, which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits.
It is commonly marketed as Elocta or Eloctate for intravenous injection. To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected in the patient populations being studied 1. The extended half-life of efmoroctocog alfa provides several clinical benefits for patients, including reduced frequency of injections required and improved adherence to prophylaxis 1.
- Protein chemical formula
- C9736H14863N2591O2855S78
- Protein average weight
- 220000.0 Da (Apparent, B-domain deleted)
- Sequences
- Not Available
- Synonyms
- Antihemophilic Factor (Recombinant BDD), FC Fusion Protein
- Antihemophilic factor (recombinant, FC fusion protein)
- Coagulation factor VIII recombinant immunoglubulin g1 fusion protein
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataEloctate Kit 750 [iU]/3mL Intravenous Bioverativ Therapeutics Inc. 2017-09-06 Not applicable US Eloctate Kit 4000 [iU]/3mL Intravenous Biogen 2014-07-14 Not applicable US Eloctate Kit 500 [iU]/3mL Intravenous Biogen 2014-07-14 Not applicable US Eloctate Kit; Powder, for solution 500 unit Intravenous Bioverativ Canada Inc 2016-01-15 Not applicable Canada Eloctate Kit; Powder, for solution 750 unit Intravenous Bioverativ Canada Inc 2016-01-15 Not applicable Canada Eloctate Kit 3000 [iU]/3mL Intravenous Bioverativ Therapeutics Inc. 2017-09-06 Not applicable US Eloctate Kit 500 [iU]/3mL Intravenous Bioverativ Therapeutics Inc. 2017-09-06 Not applicable US Eloctate Kit 2000 [iU]/3mL Intravenous Biogen 2014-07-14 Not applicable US Eloctate Kit 3000 [iU]/3mL Intravenous Biogen 2014-07-14 Not applicable US Eloctate Kit 250 [iU]/3mL Intravenous Biogen 2014-07-14 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Categories
- UNII
- 7PCM518YLR
- CAS number
- 1270012-79-7
Pharmacology
- Indication
Indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) Label.
- Associated Conditions
- Pharmacodynamics
In two multinational, open-label, noncomparative phase III trials involving previously treated pediatric and adult patients with severe haemophilia A, the clinical efficacy and safety of efmoroctocog alfa have been studied. The bleeding episodes were adequately controlled and bleeding rates were substantially reduced when efmoroctocog alfa has been used for individualized prophylaxis or treatment of bleeding Label. In adult patients receiving a single preoperative dose to maintain haemostasis during surgical procedures, the total dose on the day of surgery needed to maintain haemostasis ranged from 50.8 to 126.6 IU/kg Label.
- Mechanism of action
Factor VIII exists in a circulating protein complex consisting of two molecules via a non-covalent binding interaction; Factor VIII and von Willebrand factor. This complex remains inactive until the coagulation cascade is initiated, which activated factor VIII. Factor VIII is released from the protein complex upon activation and acts as a cofactor for factor IX-mediated conversion of factor X to activated factor X on phospholipid surfaces. Activated factor X is critical in converting prothrombin into thrombin and sequentially, thrombin converts fibrinogen to fibrin for the formation of a blood clot Label.
Haemophilia A is a X-linked hereditary disorder of blood coagulation due to decreased levels of functional factor. The disorder can lead to various disabling complications including bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma Label. Efmoroctocog alfa is a recombinant fusion protein comprised of a single molecule of B-domain deleted human coagulation factor VIII covalently linked to the Fc domain of human immunoglobulin G1. It acts as a replacement therapy to increase the plasma levels of factor VIII, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies Label.
Extended half-life of efmoroctocog alfa relative to endogenous factor VIII is explained by the Fc region binding to the neonatal Fc receptor expressed throughout life; the receptor is part of a naturally occurring pathway that protects immunoglobulins (and Fc fusion proteins) from lysosomal degradation by cycling them back into the circulation Label,1.
Target Actions Organism Avon Willebrand factor bindingHumans - Absorption
Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean peak plasma concentrations (Cmax) ranged from 108 to 131 IU/dL. Mean area under the FVIII activity time curve (AUC/Dose) ranged from 47.5 to 51.2 IUxh/dL per IU/kg. Mean AUC/Dose in adolescent patients 12 to 18 years of age ranged from 38.2 to 40.8 IUxh/dL per IU/kg. Mean AUC/Dose in pediatric patients < 12 years of age ranged from 25.9 to 38.4 IUxh/dL per IU/kg Label.
- Volume of distribution
Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean volume of distribution at steady state (Vss) ranged from 49.1 to 52.6 mL/kg. Mean Vss in adolescent patients 12 to 18 years of age ranged from 57.6 to 59.4mL/kg. Mean Vss in pediatric patients < 12 years of age ranged from 49.5 to 63.1 mL/kg Label.
- Protein binding
Like endogenous factor VIII, efmoroctocog alfa binds to von Willebrand factor in the circulation.
- Metabolism
There are no detectable metabolites for efmoroctocog alfa. It is presumed to be metabolized via a same degradation pathway as endogenous factor VIII.
- Route of elimination
- Not Available
- Half life
Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean half life (t1/2) ranged from 19 to 20.9 h. Mean t1/2 in adolescent patients 12 to 18 years of age ranged from 16 to 17.5 h. Mean t1/2 in pediatric patients < 12 years of age ranged from 12.3 to 15.9 h Label.
- Clearance
Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean clearance (CL) rate ranged from 1.95 to 2.11 mL/h/kg. Mean CL in adolescent patients 12 to 18 years of age ranged from 2.45 to 2.62 mL/h/kg. Mean t1/2 in pediatric patients < 12 years of age ranged from 2.61 to 3.86 mL/h/kg Label.
- Toxicity
Based on the findings from acute and repeated dose toxicity studies, efmoroctocog alfa displays no special hazard for humans. Studies to assess the genotoxicity, carcinogenicity, toxicity to reproduction or embryo-foetal development of efmoroctocog alfa have not been conducted. In a placental transfer study, efmoroctocog alfa has been shown to cross the placenta in small amounts in mice Label.
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn moreStructured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn moreStructured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
References
- General References
- Frampton JE: Efmoroctocog Alfa: A Review in Haemophilia A. Drugs. 2016 Sep;76(13):1281-1291. doi: 10.1007/s40265-016-0622-z. [PubMed:27487799]
- Tiede A: Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost. 2015 Jun;13 Suppl 1:S176-9. doi: 10.1111/jth.12929. [PubMed:26149020]
- External Links
- PubChem Substance
- 347911217
- AHFS Codes
- 20:28.16 — Hemostatics
- FDA label
- Download (557 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Recruiting Treatment Hemophilia / Menstrual Flow Excessive 1 1 Completed Treatment Severe Hemophilia A 1 2 Recruiting Treatment Hemophilia 1 3 Completed Other Severe Hemophilia A 1 3 Completed Treatment Hemophilia A 3 3 Withdrawn Treatment Severe Hemophilia A 1 4 Active Not Recruiting Treatment Hemophilia A 1 4 Active Not Recruiting Treatment Hemophilia A / Hemophilia A With Inhibitors 1 Not Available Active Not Recruiting Not Available Hemophilia A 1 Not Available Recruiting Not Available Haemophilia B / Hemophilia A 1 Not Available Recruiting Not Available Hemophilia 1 Not Available Terminated Not Available Hemophilia A / Hereditary factor IX deficiency 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Kit Intravenous 1000 [iU]/3mL Kit Intravenous 1500 [iU]/3mL Kit Intravenous 2000 [iU]/3mL Kit Intravenous 250 [iU]/3mL Kit Intravenous 3000 [iU]/3mL Kit Intravenous 4000 [iU]/3mL Kit Intravenous 500 [iU]/3mL Kit Intravenous 5000 [iU]/3mL Kit Intravenous 6000 [iU]/3mL Kit Intravenous 750 [iU]/3mL Kit; powder, for solution Intravenous 1000 unit Kit; powder, for solution Intravenous 1500 unit Kit; powder, for solution Intravenous 2000 unit Kit; powder, for solution Intravenous 250 unit Kit; powder, for solution Intravenous 3000 unit Kit; powder, for solution Intravenous 500 unit Kit; powder, for solution Intravenous 750 unit - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Binding
- General Function
- Protein n-terminus binding
- Specific Function
- Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
- Gene Name
- VWF
- Uniprot ID
- P04275
- Uniprot Name
- von Willebrand factor
- Molecular Weight
- 309261.83 Da
Drug created on June 24, 2016 13:15 / Updated on December 05, 2019 06:19